Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
NCT02071888
Completed
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival. To exploit the dependence of tumors on glutamine, CB-839, a potent and selective inhibitor of the first enzyme in glutamine utilization, glutaminase, will be tested in this Phase 1 study in patients with advanced hematologic malignancies. This study is an open-label Phase 1 evaluation of CB-839 in subjects with hematological tumors. Patients will receive... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2018
Locations: Mayo Clinic, Scottsdale, Arizona +6 locations
Conditions: Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM), Other B-cell NHL Subtypes, Including WM, T-cell NHL
Register for Updates
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00124579
Terminated
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as thalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. It may also stop the growth of cancer by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving b... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/13/2018
Locations: Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas +126 locations
Conditions: Multiple Myeloma
Register for Updates
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
NCT00064337
Completed
RATIONALE: Drugs used in chemotherapy such as melphalan work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving melphalan together with autologous stem cell transplantation works in treating patients with multiple myeloma or primary systemic amyloi... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/13/2018
Locations: Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas +34 locations
Conditions: Multiple Myeloma, Plasma Cell Myeloma
Register for Updates
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
NCT02491411
Terminated
This pilot trial studies how well dexamethasone and re-treatment with enzalutamide work in treating patients with prostate cancer that has spread to other places in the body (metastatic), does not respond to hormone therapy (hormone-resistant), and was previously treated with enzalutamide and docetaxel. Dexamethasone treatment may be able to reverse one resistance mechanism to enzalutamide therapy (overabundance of receptors for dexamethasone and other glucocorticoids inside cancer cells) and al... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/11/2018
Locations: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Conditions: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer
Register for Updates
Dexamethasone Plus Virtual Reality Exposure Therapy for PTSD
NCT01965366
Completed
Evidence from preliminary studies suggests that people with PTSD have heightened fear responses and that cortisol suppression reduces this heightened fear. Research has shown the drug dexamethasone (DEX), a cortisol suppressor, reduces the startle response in civilians with PTSD. This current research proposal represents a blinded, randomized, placebo-controlled efficacy study with the goal of determining whether a drug that suppresses the stress hormone cortisol will increase the efficacy of ex... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
07/10/2018
Locations: Emory University, Atlanta, Georgia
Conditions: PTSD
Register for Updates
Analgesia Duration of Dexamethasone, Buprenorphine, or Clonidine With Ropivacaine for Interscalene Nerve Block
NCT03117140
Completed
This is a prospective randomized controlled triple-masked study looking at the duration of nerve block analgesia when using the listed adjuvants (dexamethasone, buprenorphine and clonidine) plus ropivacaine versus plain ropivacaine alone.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/02/2018
Locations: University of Iowa Hospital and Clinics, Ambulatory Surgery Clinic, Iowa City, Iowa
Conditions: Anesthesia, Local
Register for Updates
A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
NCT02720510
Terminated
This was a multicenter, open-label, randomized phase II study which were to enroll 112 newly diagnosed symptomatic multiple myeloma patients in a 1:1 fashion. Patients were to enroll at approximately 20 centers in the United States. Patients were to undergo stem cell mobilization with plerixafor plus Granulocyte Colony Stimulating Factor (G-CSF), according to investigator discretion, after 4 cycles of induction therapy. Study treatment interruption for stem cell collection were not to exceed 30... Read More
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
06/26/2018
Locations: David Geffen School of Medicine at UCLA UCLA, Los Angeles, California +4 locations
Conditions: Multiple Myeloma
Register for Updates
A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting
NCT02517021
Completed
NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone. The objective of the study is to evaluate if pro-netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2018
Locations: Sarcoma Oncology Center, Santa Monica, California +73 locations
Conditions: Chemotherapy-Induced Nausea and Vomiting
Register for Updates
Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer
NCT01748942
Completed
This randomized pilot clinical trial studies dexamethasone in reducing oral pain and dry mouth after surgery in patients with oropharyngeal cancer. Dexamethasone may help lower pain and dry mouth caused by surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2018
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Dysphagia, Pain, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma
Register for Updates
Chalazion Conservative Treatment Trial
NCT01230593
Completed
An eyelid stye, or chalazion, is the most common eyelid ailment, and is caused by the blockage of one of the oil secreting glands of the eyelid (meibomian glands). This leads to a typically painful, swollen, and red eyelid bump that lasts from days to weeks and months. The chalazion may cause tearing, pressure on the cornea, and irritation, all of which contribute to its morbidity. There are many anecdotal first line treatments for this condition, including warm compresses to the eyelid, topical... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2018
Locations: Elmhurst Hospital Center, Elmhurst, New York +2 locations
Conditions: Chalazion Unspecified Eye, Unspecified Eyelid, Chalazion Left Eye, Unspecified Eyelid, Chalazion Right Eye, Unspecified Eyelid, Chalazion Both Eyes
Register for Updates
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
NCT01692197
Completed
The goal of this clinical research study is to learn if E7070 in combination with idarubicin, cytarabine, and dexamethasone can help to control the disease in patients with either AML or high-risk MDS that has relapsed. The safety of the drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2018
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Register for Updates
Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma
NCT00538824
Terminated
Study Objectives 1. To evaluate the efficacy of the combination of dexamethasone (Decadron®), thalidomide (Thalomid®), and lenalidomide (Revlimid®) as therapy for patients with relapsed or refractory multiple myeloma (MM) who have failed prior treatment with both lenalidomide and thalidomide when used as monotherapies. 2. To evaluate the safety of the combination of lenalidomide, dexamethasone, and thalidomide as a therapy for patients with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2018
Locations: Weill Medical College of Cornell University, New York, New York
Conditions: Multiple Myeloma
Register for Updates